Ovidrel and Trazodone Interaction: What You Need to Know Before Your Trigger Shot

The Short Answer: No Clinically Significant Drug-Drug Interaction

There is no established pharmacokinetic drug-drug interaction between Ovidrel and trazodone. The two drugs act on entirely separate receptor systems and are metabolized through different pathways, meaning one does not meaningfully change the blood levels or efficacy of the other. The FDA prescribing information for choriogonadotropin alfa lists no CYP-mediated interactions because the molecule is a glycoprotein hormone broken down by proteolytic enzymes, not by the cytochrome P450 system.

Two women talking about this topic on a fertility forum are not asking an idle question. Many women undergoing IVF or timed intercourse cycles take trazodone at low doses (25 to 100 mg) to manage the sleep disruption and anxiety that accompany assisted reproduction. Understanding exactly why the interaction is minor, and where a small caution still applies, helps you walk into your clinic visit with the right questions.

What Ovidrel Actually Is

Ovidrel is a recombinant human chorionic gonadotropin (hCG) alfa, a 237-amino-acid glycoprotein identical in structure to the hCG produced by a developing placenta. A single subcutaneous injection of 250 mcg is the standard trigger dose used to induce final oocyte maturation 36 hours before egg retrieval or timed intercourse, as confirmed in the European clinical trial that supported FDA approval.

Because it is a peptide, Ovidrel is not a substrate for CYP1A2, CYP2D6, CYP3A4, or P-glycoprotein. It does not enter the hepatic CYP machinery at all. Elimination occurs through the kidneys and through proteolytic degradation, with a mean terminal half-life of approximately 29 hours after a 250-mcg subcutaneous dose.

What Trazodone Actually Is

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) approved for major depressive disorder but widely prescribed off-label for insomnia at doses of 25 to 100 mg. It is primarily metabolized by CYP3A4 to its active metabolite m-chlorophenylpiperazine (mCPP), with minor contributions from CYP2D6. It also has significant histamine H1 and alpha-1 adrenergic antagonism, which drives its sedative effect.

Because Ovidrel has zero CYP3A4 or CYP2D6 involvement, trazodone cannot accelerate or slow Ovidrel's clearance. The pharmacokinetic half of the interaction question is closed.

Where a Real Concern Does Exist: Pharmacodynamic Sedation

This is the one place where a small clinical flag applies. Trazodone produces sedation through H1 blockade and alpha-1 antagonism. On trigger-shot night, many women also experience fatigue from the preceding days of gonadotropin stimulation, mild pelvic discomfort from follicle enlargement, and emotional exhaustion. Layering trazodone's sedation on top of an already fatigued physiologic state may intensify next-morning grogginess.

This is a pharmacodynamic overlap, not a pharmacokinetic one. No published case reports or controlled trials document a clinically dangerous outcome from this specific combination. The FDA trazodone labeling warns generally about additive CNS depression when trazodone is combined with other sedating agents or alcohol, and this general principle extends logically to the fatigue of ovarian stimulation cycles.

Practical Guidance for Trigger-Shot Night

• Take trazodone at your usual time if your reproductive endocrinologist has confirmed it is appropriate to continue.
• Avoid combining trazodone with antihistamines, benzodiazepines, or alcohol on the same night.
• Plan to have eight full hours available for sleep so grogginess resolves before any driving.
• If your center schedules egg retrieval 36 hours post-trigger, you will likely be awake and ambulatory well before you need to leave the house.

Does Sedation Affect the Trigger's Efficacy?

No. Ovidrel works by binding to the LH/FSH receptor on granulosa and theca cells of the mature follicle. Sedation does not alter receptor binding. The phase III trial of choriogonadotropin alfa (Penzias et al., Fertility and Sterility) showed consistent ovulation induction rates regardless of concurrent medications provided they had no CYP-mediated interference with the drug itself.

Sex-Specific Physiology: Why This Matters Specifically for Women

The Menstrual Cycle and Trazodone

Trazodone's sedative effect can vary across the cycle. In the luteal phase, progesterone has mild GABA-A modulating properties that may compound trazodone's sedation slightly. Women in the late stimulation phase of an IVF cycle have supraphysiologic estrogen levels, which can modestly affect serotonin receptor sensitivity. There are no controlled trial data quantifying this effect specifically, and the clinical significance is likely minor, but it is one more reason to use the lowest effective trazodone dose during an active fertility cycle.

PCOS and Trazodone

Women with polycystic ovary syndrome (PCOS) are a significant subset of Ovidrel users. PCOS is associated with higher rates of anxiety and depression, and trazodone for sleep is a reasonable choice in this population because, unlike some antidepressants, it does not carry strong evidence of significant weight gain or menstrual cycle disruption at low sleep doses. A 2022 systematic review in the Journal of Clinical Endocrinology and Metabolism noted elevated depression prevalence in women with PCOS, supporting the clinical reality that many Ovidrel users will also be managing a mood or sleep disorder.

Anxiety, Insomnia, and IVF: The Bigger Picture

The WomanRx clinical framework for managing sleep during an ART cycle distinguishes three phases where trazodone use requires separate evaluation:

Phase 1 (stimulation days 1 to 10): Trazodone at 25 to 50 mg for sleep is generally compatible with gonadotropin injections (FSH, LH, menotropins) because none of these peptide hormones interact with CYP3A4. Confirm with your RE team if you are also taking oral medications such as letrozole or clomiphene, which do have different metabolic profiles.

Phase 2 (trigger night): As described above, additive sedation is the only concern. Use the lowest effective dose and plan for a full night's sleep.

Phase 3 (post-retrieval or two-week wait): If a progesterone suppository or injectable progesterone is added, note that neither interacts pharmacokinetically with trazodone. Sedation overlap remains the only flag.

Pregnancy and Lactation Safety (Required Reading)

This section is required for every drug article on WomanRx, and for Ovidrel users it carries unique nuance because the goal of treatment is pregnancy.

Ovidrel in Pregnancy

Ovidrel carries an FDA Pregnancy Category X designation for use during pregnancy. This sounds alarming but requires context. The Category X designation does not mean the drug is a known teratogen in the traditional sense. It means Ovidrel is intended to trigger ovulation, and administering it after a pregnancy is already established serves no clinical purpose while carrying theoretical risk from supraphysiologic hCG exposure. The window of Ovidrel use (a single injection given before confirmed pregnancy) does not itself pose a teratogenic risk. HCG is a natural pregnancy hormone; the concern is iatrogenic superstimulation, not birth defects.

If you receive a positive pregnancy test within two weeks of the trigger shot, the residual Ovidrel signal will clear within approximately 10 days post-injection at the 250-mcg dose, which is why many fertility centers advise waiting at least 14 days before home testing to avoid a false-positive from the exogenous hCG.

Trazodone in Pregnancy

Trazodone in pregnancy has a much thinner evidence base than SSRIs. The drug is not a Pregnancy Category D or X agent, but human data remain limited. Animal reproduction studies showed no teratogenicity at doses below maternal toxicity thresholds. A 2013 prospective cohort study in the British Journal of Clinical Pharmacology found no significant increase in major malformations with first-trimester trazodone exposure compared to non-teratogenic controls, though the sample size was small.

Current clinical practice, per ACOG Practice Bulletin guidance on depression in pregnancy, recommends weighing the risk of untreated depression against medication exposure. If you are using trazodone solely as a sleep aid at low doses and you conceive, discuss transition options with your OB or psychiatrist promptly. SSRIs with longer pregnancy safety records (such as sertraline) may be preferred for ongoing treatment.

Trazodone and Lactation

Trazodone transfers into breast milk in low concentrations. A pharmacokinetic study published in the Journal of Clinical Psychiatry found a relative infant dose of approximately 0.77 to 2.8%, which is below the generally accepted 10% safety threshold. The American Academy of Pediatrics classifies trazodone as a drug for which the effect on nursing infants is unknown but may be of concern. Sedation in the nursing infant is the primary watch point. If you are postpartum and considering trazodone for sleep, discuss timing of doses (immediately after the last evening feed) with your provider.

Contraception Note

Because Ovidrel is used to trigger ovulation, contraception is not relevant during active fertility treatment. Women who receive Ovidrel outside of a formal fertility protocol (which would be off-label and unusual) should be counseled that the drug actively facilitates fertilization.

Who This Combination Is Appropriate For, and Who Should Pause

Women for Whom Continuing Trazodone Through an Ovidrel Cycle Is Reasonable

• You have documented insomnia that is worsening due to cycle-related anxiety and sleep disruption.
• Your reproductive endocrinologist and prescribing clinician have both reviewed your medication list and agreed to continue.
• You are using trazodone at 25 to 100 mg for sleep only, not at antidepressant doses (typically 150 to 400 mg).
• You have no additional CNS-sedating medications or substances layered on top.

Women Who Should Have a Dedicated Medication Review Before Proceeding

• You are taking trazodone at higher antidepressant doses (150 mg or above) combined with other serotonergic drugs (SSRIs, SNRIs, buspirone), because serotonin syndrome, while rare, is a documented trazodone risk and concurrent fertility drugs do not reduce that risk.
• You have significant hepatic impairment, which would slow trazodone's CYP3A4-mediated clearance, extending sedation duration.
• You are planning oocyte or embryo donation and the medication schedule is particularly time-sensitive.
• You have a history of ovarian hyperstimulation syndrome (OHSS), which can cause significant discomfort requiring clear-headedness to recognize warning symptoms. Heavy sedation on trigger night could theoretically delay recognition of severe OHSS symptoms, though this risk is speculative rather than evidence-based.

What the Evidence Gap Looks Like

Women have been under-represented in pharmacokinetic drug-drug interaction studies for decades. Neither the Ovidrel NDA clinical program nor the trazodone clinical database includes a dedicated interaction study pairing these two drugs, because the pairing was not anticipated as a high-priority safety signal. The FDA choriogonadotropin alfa label lists no formal drug interaction studies at all, a direct consequence of the drug's peptide nature and lack of CYP involvement.

What this means for you: the reassurance that no interaction exists is mechanistically grounded but not empirically confirmed in a controlled trial of women taking both drugs simultaneously. The mechanistic reasoning is sound. The absence of a controlled trial is the honest caveat.

A 2019 review in Fertility and Sterility on psychotropic medication use during ART cycles noted that data on most non-SSRI psychotropics during stimulation cycles are absent from the literature, and clinical decisions default to mechanistic reasoning and individual risk-benefit assessment.

How to Have the Conversation With Your Fertility Team

Many women feel hesitant to disclose psychiatric or sleep medications to their reproductive endocrinologist, fearing judgment or a recommendation to stop a drug that is genuinely helping them function through a stressful treatment cycle. That hesitation is understandable and common.

Bring the following to your next appointment:

• The name, dose, and frequency of trazodone you are taking.
• The reason you are taking it (sleep, depression, or both).
• Who originally prescribed it, so your RE can loop in that clinician if needed.
• Any other medications, supplements, or herbal products (valerian, melatonin, and CBD all have sedative properties that compound trazodone's effect).

Your reproductive endocrinologist may also ask whether you have tried non-pharmacologic sleep interventions such as cognitive behavioral therapy for insomnia (CBT-I), which a Cochrane review found effective without medication-related risks. CBT-I is worth discussing as an adjunct or alternative for women who want to minimize pharmacologic load during active fertility treatment.

Monitoring and Dose Considerations

No Ovidrel Dose Adjustment Needed

There is no basis for adjusting the standard 250-mcg Ovidrel subcutaneous dose based on concurrent trazodone use. The trigger dose is fixed by the physiology of follicle maturation, not by drug metabolism variables.

Consider Lowest Effective Trazodone Dose

If you are using trazodone purely for sleep, doses of 25 to 50 mg are often as effective as 100 mg for sleep induction, with less next-morning sedation. This is a reasonable harm-reduction approach on trigger-shot night specifically. A dose reduction should be discussed with the prescribing clinician, not made unilaterally.

Timing on Trigger Night

Taking trazodone at 9 to 10 PM on a trigger night that starts at midnight means peak plasma trazodone concentrations (reached within 1 to 2 hours of dosing) occur before the injection is due. By the time your alarm goes off for the midnight trigger, the drug is on its way to clearance. This self-directed timing adjustment has not been studied but follows straightforwardly from trazodone's pharmacokinetic profile.

Key Takeaways for Your Next Clinic Visit

There is no pharmacokinetic interaction between Ovidrel and trazodone. Ovidrel is a glycoprotein hormone cleared by proteolysis, not by the CYP enzymes that trazodone relies on. The only clinically relevant overlap is additive sedation on trigger-shot night, which is manageable through dose timing and using the lowest effective trazodone dose. Trazodone in pregnancy has limited but not alarming human safety data, and any decision to continue or stop it after conception should involve the prescribing clinician promptly.

The standard evidence-based trigger dose for Ovidrel remains 250 mcg subcutaneously administered 36 hours before planned egg retrieval or timed intercourse, and nothing about concurrent trazodone use at sleep doses changes that protocol.